Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sophiris Eyes Another Phase III After Positive BPH Results

This article was originally published in Scrip

Executive Summary

Sophiris Bio Inc. bounced back from a negative interim efficacy report when the company revealed positive results from the Phase III PLUS-1 clinical trial for PRX302 (topsalysin) in the treatment of urinary tract symptoms associated with benign prostatic hyperplasia (BPH), or an enlarged prostate, on Nov. 10.

You may also be interested in...

Patient Death Obscures Efficacy Success For Sophiris’ Intratumoral Prostate Cancer Therapy

The bad outweighed the good for Sophiris on a day in which it unveiled promising Phase IIb data for topsalysin, but also took a huge stock hit with news of a patient death in the trial.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

Anti-BCMA Therapies Aim To Raise The Bar In Myeloma

GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts